Home > Compound List > Product Information
Anisindione_Molecular_structure_CAS_117-37-3)
Click picture or here to close

Anisindione

Catalog No. DB01125 Name DrugBank
CAS Number 117-37-3 Website http://www.ualberta.ca/
M. F. C16H12O3 Telephone (780) 492-3111
M. W. 252.26468 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 996

SYNONYMS

IUPAC name
2-(4-methoxyphenyl)-2,3-dihydro-1H-indene-1,3-dione
IUPAC Traditional name
anisindione
Brand Name
Unidone
Miradon
Synonyms
Anisin indandione

DATABASE IDS

CAS Number 117-37-3
PubChem SID 46504660
PubChem CID 2197

PROPERTIES

Hydrophobicity(logP) 2.6
Solubility 79.8 mg/L

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Anisindione is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K-mediated gamma-carboxylation of precursor proteins.
Indication For the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion.
Pharmacology Anisindione is a synthetic anticoagulant and an indanedione derivative. It is prescribed only if you cannot take coumarin-type anticoagulants such as coumadin as anisindione is a powerful drug with serious potential side effects. Anticoagulants decrease the clotting ability of the blood and therefore help to prevent harmful clots from forming in the blood vessels. These medicines are sometimes called blood thinners, although they do not actually thin the blood. They also will not dissolve clots that already have formed, but they may prevent the clots from becoming larger and causing more serious problems.
Toxicity An overdose is likely to cause abnormal bleeding, for which the symptoms include: bleeding from gums or nose, blood in urine or stools, excessive bleeding from minor cuts, patches of discoloration or bruises on the skin.
Affected Organisms
Humans and other mammals
Absorption Accumulation does not occur with repeated dosing.
Half Life Not Known
Protein Binding Not Known
References
CONNELL WF, MAYER GA: Evaluation of anticoagulant therapy with anisindione (miradon). Can Med Assoc J. 1959 May 15;80(10):785-90. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

REFERENCES

  • CONNELL WF, MAYER GA: Evaluation of anticoagulant therapy with anisindione (miradon). Can Med Assoc J. 1959 May 15;80(10):785-90. Pubmed